71659-82-0Relevant articles and documents
Process development for sodelglitazar: A ppar panagonist
Brown, Andrew D.,Davis, Roman D.,Fitzgerald, Russ N.,Glover, Bobby N.,Harvey, Kim A.,Jones, Lynda A.,Liu, Bing,Patterson, Daniel E.,Sharp, Matthew J.
experimental part, p. 297 - 302 (2010/04/22)
Three efficient syntheses of sodelglitazar (1) have been developed. In particular, the third synthesis avoids the use of zinc and eliminates the resulting heavy metal waste stream as well as the potential genotoxic methanesulfonate in the two earlier syntheses. This process produces sodelglitazar in 74% overall yield from readily available thiophenol (8) and thiazole alcohol (3).
Development of a scalable synthesis of GSK183390A, a PPAR α/γ agonist
Oh, Lynette M.,Wang, Huan,Shilcrat, Susan C.,Hermann, Robert E.,Patience, Daniel B.,Spoors, P. Grant,Sisko, Joseph
, p. 1032 - 1042 (2012/12/30)
A scalable synthesis of GSK183390A, a PPAR α/γ agonist, is described. This synthesis is highlighted by (1) a regioselective formal 1,3-dipolar cycloaddition reaction between an enamine and a nitrile inline dipole to form a 1,3,5-trisubstmited pyrazole and (2) a regioselective amidomethylation of an o-cresol derivative using 2-chloro-JV- hydroxymethylacetamide.
4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
-
Page/Page column 18, (2010/10/20)
The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.
